CL2013000596A1 - Moleculas de union a vegf; molecula de acido nucleico que la codifica; celula hospedante; composicion farmaceutica; uso de la composicion para tratar efectos sobre la angiogenesis mediados por el vegf. - Google Patents

Moleculas de union a vegf; molecula de acido nucleico que la codifica; celula hospedante; composicion farmaceutica; uso de la composicion para tratar efectos sobre la angiogenesis mediados por el vegf.

Info

Publication number
CL2013000596A1
CL2013000596A1 CL2013000596A CL2013000596A CL2013000596A1 CL 2013000596 A1 CL2013000596 A1 CL 2013000596A1 CL 2013000596 A CL2013000596 A CL 2013000596A CL 2013000596 A CL2013000596 A CL 2013000596A CL 2013000596 A1 CL2013000596 A1 CL 2013000596A1
Authority
CL
Chile
Prior art keywords
vegf
composition
union
encodes
molecules
Prior art date
Application number
CL2013000596A
Other languages
English (en)
Inventor
Andreas Gschwind
Eric Borges
Joachim Boucneau
Tavernier Evelyn De
Joost Kolkman
Pascal Merchiers
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43530923&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000596(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2013000596A1 publication Critical patent/CL2013000596A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CL2013000596A 2010-09-03 2013-03-01 Moleculas de union a vegf; molecula de acido nucleico que la codifica; celula hospedante; composicion farmaceutica; uso de la composicion para tratar efectos sobre la angiogenesis mediados por el vegf. CL2013000596A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10175318 2010-09-03

Publications (1)

Publication Number Publication Date
CL2013000596A1 true CL2013000596A1 (es) 2014-02-14

Family

ID=43530923

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000596A CL2013000596A1 (es) 2010-09-03 2013-03-01 Moleculas de union a vegf; molecula de acido nucleico que la codifica; celula hospedante; composicion farmaceutica; uso de la composicion para tratar efectos sobre la angiogenesis mediados por el vegf.

Country Status (16)

Country Link
US (6) US20120225081A1 (es)
EP (2) EP2727939A3 (es)
JP (1) JP5979504B2 (es)
KR (1) KR101844875B1 (es)
CN (1) CN103209995B (es)
AR (1) AR082892A1 (es)
AU (1) AU2011298281B2 (es)
BR (1) BR112013005151A2 (es)
CA (1) CA2808696C (es)
CL (1) CL2013000596A1 (es)
EA (1) EA029277B1 (es)
IL (1) IL224800B (es)
MX (1) MX353813B (es)
NZ (1) NZ607394A (es)
UY (1) UY33588A (es)
WO (1) WO2012028716A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
WO2014031856A1 (en) * 2012-08-23 2014-02-27 Onconthyreon Inc. Combination therapy using pi3 kinase and braf inhibitors
KR101541478B1 (ko) * 2013-05-31 2015-08-05 동아쏘시오홀딩스 주식회사 항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물
US9388239B2 (en) * 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
WO2016109943A1 (zh) * 2015-01-06 2016-07-14 珠海亿胜生物制药有限公司 抗vegf抗体
MX2018010824A (es) * 2016-03-08 2019-05-15 Maverick Therapeutics Inc Proteinas de union inducibles y metodos de uso.
CN110248674B (zh) * 2016-09-07 2021-10-26 萨辛生命科学有限公司 针对vegf的合成抗体及其用途
TW201840584A (zh) * 2017-03-20 2018-11-16 美商歐樂根公司 針對vegf之僅含重鏈之抗體
JP7268005B2 (ja) 2017-09-08 2023-05-02 武田薬品工業株式会社 拘束され、条件的に活性化された結合タンパク質
JP2022524338A (ja) 2019-03-05 2022-05-02 武田薬品工業株式会社 拘束され、条件的に活性化された結合タンパク質
CN110452297B (zh) * 2019-09-03 2020-04-14 上海洛启生物医药技术有限公司 抗vegf单域抗体及其应用
MX2023001490A (es) 2020-08-05 2023-04-27 Synthekine Inc Moleculas de union a il27r\03b1 y metodos de uso.
AU2022222311A1 (en) * 2021-02-19 2023-09-21 Dotbio Pte. Ltd. Vegfa-binding molecules
CA3229250A1 (en) * 2021-08-13 2023-02-16 Innovent Biologics (Suzhou) Co., Ltd. Anti-vegf a and vegf c bispecific antibodies and use thereof
CN115724968B (zh) * 2021-08-27 2023-08-08 三优生物医药(上海)有限公司 Vegf结合分子及其用途
CN113896805B (zh) * 2021-12-13 2022-02-25 上海惠盾因泰生物科技有限公司 一种vegf-crm197重组融合蛋白疫苗及其制备方法和应用
WO2024055996A1 (zh) * 2022-09-14 2024-03-21 寻济生物科技（北京）有限公司 一种抗vegfa抗体或其抗原结合片段及其应用
CN116284405B (zh) * 2023-03-15 2024-03-19 中国科学技术大学 靶向cd150蛋白的纳米抗体及其应用
CN118085081B (zh) * 2024-04-19 2024-06-21 云南大学 一种特异性结合vegf的纳米抗体及用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0656946T4 (da) 1992-08-21 2010-07-26 Univ Bruxelles Immunoglobuliner uden lette kæder
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
EP2267026A1 (en) 2000-04-12 2010-12-29 Human Genome Sciences, Inc. Albumin fusion proteins
CN1911965B (zh) 2001-01-17 2013-05-29 新兴产品开发西雅图有限公司 结合域-免疫球蛋白融合蛋白
EP1399484B1 (en) 2001-06-28 2010-08-11 Domantis Limited Dual-specific ligand and its use
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
AU2003286003B2 (en) 2002-11-08 2011-05-26 Ablynx N.V. Stabilized single domain antibodies
WO2004041865A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Stabilized single domain antibodies
US20050043220A1 (en) * 2002-11-08 2005-02-24 Guyer David R. Methods and compositions for treating macular degeneration
DE60329627D1 (de) 2002-12-31 2009-11-19 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
CA2529819A1 (en) 2003-06-30 2004-09-23 Domantis Limited Pegylated single domain antibodies
ATE485307T1 (de) 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
US20050284249A1 (en) 2004-06-29 2005-12-29 Arnone David F Worm type gear mover assembly
KR20070084170A (ko) 2004-10-13 2007-08-24 아블린쓰 엔.브이. 알쯔하이머병 등의 퇴행성 신경 질환의 치료 및 진단을위한 단일 도메인 카멜리드 항-아밀로이드 베타 항체 및이를 포함하는 폴리펩타이드
CN103254309B (zh) 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
EP2029159A2 (en) 2006-06-06 2009-03-04 Genentech, Inc. Compositions and methods for modulating vascular development
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
JP2010507594A (ja) * 2006-10-20 2010-03-11 シェーリング コーポレイション 完全ヒト抗ｖｅｇｆ抗体および使用方法
CA2678218A1 (en) * 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
US8216571B2 (en) * 2007-10-22 2012-07-10 Schering Corporation Fully human anti-VEGF antibodies and methods of using
WO2009095489A2 (en) 2008-02-01 2009-08-06 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
CA2717015A1 (en) 2008-03-05 2009-09-11 Ablynx Nv Novel antigen binding dimer-complexes, methods of making and uses thereof
WO2010124009A2 (en) * 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
UY32920A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis

Also Published As

Publication number Publication date
IL224800B (en) 2020-03-31
CN103209995A (zh) 2013-07-17
EA029277B1 (ru) 2018-03-30
JP5979504B2 (ja) 2016-08-24
UY33588A (es) 2012-03-30
KR20130101045A (ko) 2013-09-12
US20240141030A1 (en) 2024-05-02
JP2013541939A (ja) 2013-11-21
AR082892A1 (es) 2013-01-16
BR112013005151A2 (pt) 2020-08-04
US20120225081A1 (en) 2012-09-06
EP2727939A3 (en) 2014-05-21
MX2013002379A (es) 2013-05-09
EA201300311A1 (ru) 2013-08-30
US20220363744A1 (en) 2022-11-17
CA2808696C (en) 2016-12-20
US20160200806A1 (en) 2016-07-14
US20200308267A1 (en) 2020-10-01
AU2011298281A1 (en) 2013-03-14
KR101844875B1 (ko) 2018-04-03
CN103209995B (zh) 2015-11-25
NZ607394A (en) 2014-12-24
AU2011298281B2 (en) 2015-02-05
WO2012028716A1 (en) 2012-03-08
EP2611830A1 (en) 2013-07-10
MX353813B (es) 2018-01-31
CA2808696A1 (en) 2012-03-08
EP2727939A2 (en) 2014-05-07
US20180201671A1 (en) 2018-07-19

Similar Documents

Publication Publication Date Title
CL2013000596A1 (es) Moleculas de union a vegf; molecula de acido nucleico que la codifica; celula hospedante; composicion farmaceutica; uso de la composicion para tratar efectos sobre la angiogenesis mediados por el vegf.
CY2023019I2 (el) Bcma (cd269/tnfrsf17) - πρωτεϊνες δεσμευσης
CL2014000631A1 (es) Molecula de union que se une a cd134 (ox40); molecula de acido nucleico que la codifica; vector; celula huesped; proceso de preparacion; composicion farmaceutica que la comprende; y su uso para tratar cancer.
CL2009000379A1 (es) Anticuerpo monoclonal aislado especifico contra los ligandos angiopoyetina 1 y 2 del receptor tie 2; fragmento del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso para inhibir la angiogenesis no deseada tal como cancer.
CL2014002750A1 (es) Anticuerpo aislado o fragmento que se enlaza a un estado inactiva de un receptor her; composición farmacéutica que lo comprende; uso del anticuerpo para tratar cancer
CL2014002072A1 (es) Polipéptidos de unión a cx3cr1; molecula de acido nucleico que lo codifica; composicion farmaceutica que lo contiene; metodo de elaboracion del peptido; usos del peptido; kit que contiene el peptido.
CL2015000094A1 (es) Compuestos derivados de imidazotriazincarbonitrilos, inhibidores de la proteina cinasa; composicion farmaceutica que los comprende; y su uso para tratar el cancer, psoriasis y artritis reumatoide.
CL2013000669A1 (es) Agente de union a cd33 que se une al cd33 humano; molecula de adn que codifica la region variable de cadena pesada de un agente de union a cd33; vector de expresion; celula hospedante; metodo para reducir agente de unión a cd33; composicion farmaceutica; uso de la composicion farmaceutica para disminuir el numero de celulas que expresan el cd33 sobre su superficie.
BR112012012108A2 (pt) composição farmacêutica compreendendo propofol
BR112015003570A2 (pt) composições de cimento ou de argamassa multi-uso para aplicações em construção.
BRPI0925099A2 (pt) composição tópica contendo ibuprofeno
BR112014012681A2 (pt) polipeptídeo, métido para proporcionar um polipeptídeo, ácido nucleico, e, composição imunogênica
BR112013011705A2 (pt) antígenos consensuais de próstata, molécula de ácido nucleico que os codificam e vacina e usos que os compreendem
CL2013000930A1 (es) Anticuerpo para interleuquina 17 (il-17); uso de dicho anticuerpo para tratar soriasis usando antagonistas de il-17.
DK3192501T3 (da) Topisk farmaceutisk sammensætning baseret på semifluorerede alkaner
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
DK2421879T3 (da) Nye 7-deazapurinnukleotider til terapeutiske anvendelser
CL2013001290A1 (es) Anticuerpo aislado, o su fragmento, que se une a beta secretasa (bace1); acido nucleico que codifica el anticuerpo; celula huesped que comprende el acido nucleico; metodo para producir un anticuerpo; inmunoconjugado que comprende el anticuerpo; formulacion farmaceutica; uso del anticuerpo para tratar enfermedad o trastorno neurológico.
DK2654736T3 (da) Hidtil ukendt farmaceutisk sammensætning
CL2012001143A1 (es) Anticuerpo anti-fractalkina (anti-fkn); composicion farmaceutica que comprende dicho anticuerpo anti-fkn; acido nucleico; vector; celula huesped; uso del anticuerpo anti-fkn para tratar trastornos inflamatorios.
CL2014003535A1 (es) Compuestos derivados de fenoxietil piperidina; composicion farmaceutica y uso para tratar la osteoartritis, artritis reumatoidea y el dolor asociado.
BR112013010169A8 (pt) uso de monascus na produção de ácido orgânico.
CL2014003167A1 (es) Molécula de unión que se une específicamente a inteleuquina 6 (il-6); composición farmacéutica que la comprende; ácido nucleico; vector; célula huésped; y uso para tratar enfermedad o trastorno asociado a il-6.
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
BR112014000767A2 (pt) composição de polímero dendrímero de elevado teor de sólidos